---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000053"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:33:22.477237+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused

## Summary
- FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.
- Patients currently enrolled who derive clinical benefit may continue treatment per ongoing protocol.
- Hold follows Nurix's communication to FDA of intention to transition to an improved manufacturing process.
- Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement.

## SEC filing metadata
- accession: 0001549595-23-000053
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000053/0001549595-23-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000053/nrix-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000053
- JSON: https://secwatch.observer/filing/0001549595-23-000053.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.